Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO-016 trial

Agnieszka Wierzbowska; Ewa Wawrzyniak; Agnieszka Pluta; Tadeusz Robak; Grzegorz J. Mazur; Anna Dmoszynska; Jaroslav Cermak; Albert Oriol; Daniel Lysak; Chris Arthur; Margaret Doyle; Liang Xiu; Farhad Ravandi; Hagop M. Kantarjian

doi:10.1002/ajh.25062

Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO-016 trial

Agnieszka Wierzbowska, Ewa Wawrzyniak, Agnieszka Pluta, Tadeusz Robak, Grzegorz J. Mazur, Anna Dmoszynska, Jaroslav Cermak, Albert Oriol, Daniel Lysak, Chris Arthur, Margaret Doyle, Liang Xiu, Farhad Ravandi, Hagop M. Kantarjian

Leukemia

Research output: Contribution to journal › Letter › peer-review

14 Scopus citations

Original language	English (US)
Pages (from-to)	E125-E127
Journal	American journal of hematology
Volume	93
Issue number	5
DOIs	https://doi.org/10.1002/ajh.25062
State	Published - May 2018

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.25062

Cite this

Wierzbowska, A., Wawrzyniak, E., Pluta, A., Robak, T., Mazur, G. J., Dmoszynska, A., Cermak, J., Oriol, A., Lysak, D., Arthur, C., Doyle, M., Xiu, L., Ravandi, F., & Kantarjian, H. M. (2018). Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO-016 trial. American journal of hematology, 93(5), E125-E127. https://doi.org/10.1002/ajh.25062

Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO-016 trial. / Wierzbowska, Agnieszka; Wawrzyniak, Ewa; Pluta, Agnieszka et al.
In: American journal of hematology, Vol. 93, No. 5, 05.2018, p. E125-E127.

Research output: Contribution to journal › Letter › peer-review

Wierzbowska, A, Wawrzyniak, E, Pluta, A, Robak, T, Mazur, GJ, Dmoszynska, A, Cermak, J, Oriol, A, Lysak, D, Arthur, C, Doyle, M, Xiu, L, Ravandi, F & Kantarjian, HM 2018, 'Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO-016 trial', American journal of hematology, vol. 93, no. 5, pp. E125-E127. https://doi.org/10.1002/ajh.25062

@article{eb5c725f0fac4d0495b6c8ac134d4548,

title = "Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO-016 trial",

author = "Agnieszka Wierzbowska and Ewa Wawrzyniak and Agnieszka Pluta and Tadeusz Robak and Mazur, {Grzegorz J.} and Anna Dmoszynska and Jaroslav Cermak and Albert Oriol and Daniel Lysak and Chris Arthur and Margaret Doyle and Liang Xiu and Farhad Ravandi and Kantarjian, {Hagop M.}",

note = "Funding Information: Under the direction of the authors, medical writing services for early versions of the manuscript were provided by Dr. Timothy Ryder of Rocket Science Medical Communications Limited. Medical writing services were funded by Janssen Pharmaceutical Companies of Johnson & Johnson in Europe. Funding Information: A.W. reports consultancy for Celgene, Janssen, and Novartis, and speaker bureau participation for Celgene and Janssen. T.R. reports consultancy, sponsorship and research funding from Janssen. A.O. reports consultancy and speaker bureau participation for Amgen, Janssen, and Takeda. D.L. reports consultancy for Abbvie and Roche, and speaker bureau participation for Janssen. M.D. and L.X. are full-time employees and stockholders in Janssen. F.R. reports consultancy for Amgen, Seattle Genetics, and Sunesis, and research funding from Amgen, BMS, Seattle Genetics, Sunesis, and Xencor. H.M.K. reports consultancy for Abbvie, Actinium, Amgen, Ariad, BMS, Immunogen, Orsinex, and Pfizer, and research funding from Amgen, Ariad, Astex, BMS, Novartis, and Pfizer. E.W., A.P., G.J.M., A.D., J.C., and C.A. have no relevant conflicts of interest to disclose.",

year = "2018",

month = may,

doi = "10.1002/ajh.25062",

language = "English (US)",

volume = "93",

pages = "E125--E127",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "5",

}

TY - JOUR

T1 - Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype

T2 - A subgroup analysis of the DACO-016 trial

AU - Wierzbowska, Agnieszka

AU - Wawrzyniak, Ewa

AU - Pluta, Agnieszka

AU - Robak, Tadeusz

AU - Mazur, Grzegorz J.

AU - Dmoszynska, Anna

AU - Cermak, Jaroslav

AU - Oriol, Albert

AU - Lysak, Daniel

AU - Arthur, Chris

AU - Doyle, Margaret

AU - Xiu, Liang

AU - Ravandi, Farhad

AU - Kantarjian, Hagop M.

N1 - Funding Information: Under the direction of the authors, medical writing services for early versions of the manuscript were provided by Dr. Timothy Ryder of Rocket Science Medical Communications Limited. Medical writing services were funded by Janssen Pharmaceutical Companies of Johnson & Johnson in Europe. Funding Information: A.W. reports consultancy for Celgene, Janssen, and Novartis, and speaker bureau participation for Celgene and Janssen. T.R. reports consultancy, sponsorship and research funding from Janssen. A.O. reports consultancy and speaker bureau participation for Amgen, Janssen, and Takeda. D.L. reports consultancy for Abbvie and Roche, and speaker bureau participation for Janssen. M.D. and L.X. are full-time employees and stockholders in Janssen. F.R. reports consultancy for Amgen, Seattle Genetics, and Sunesis, and research funding from Amgen, BMS, Seattle Genetics, Sunesis, and Xencor. H.M.K. reports consultancy for Abbvie, Actinium, Amgen, Ariad, BMS, Immunogen, Orsinex, and Pfizer, and research funding from Amgen, Ariad, Astex, BMS, Novartis, and Pfizer. E.W., A.P., G.J.M., A.D., J.C., and C.A. have no relevant conflicts of interest to disclose.

PY - 2018/5

Y1 - 2018/5

UR - http://www.scopus.com/inward/record.url?scp=85042398067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042398067&partnerID=8YFLogxK

U2 - 10.1002/ajh.25062

DO - 10.1002/ajh.25062

M3 - Letter

C2 - 29417613

AN - SCOPUS:85042398067

SN - 0361-8609

VL - 93

SP - E125-E127

JO - American journal of hematology

JF - American journal of hematology

IS - 5

ER -

Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO-016 trial

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this